Current position

Joel Greenblatt’s Axsome Therapeutics Inc. (AXSM) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Gotham Asset ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2019Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares11.16KHighest verified quarter-end share count
Quarters reported3Verified quarters with shares above zero
What happened?

Gotham Asset Management first reported Axsome Therapeutics Inc. in Q2 2019. After an earlier exit, the position later appeared again in a verified filing. Gotham Asset Management currently reports 980 shares. The latest verified filing showed: New position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
New position+980 shares · 980 shares reported
Filing context

Quarter-end price $244.77 · Estimated holding basis $244.77

Q1 2020
Sold the entire position−2.50K shares · No shares reported at quarter-end
Q4 2019
New position+2.50K shares · 2.50K shares reported
Filing context

Quarter-end price $103.41 · Estimated holding basis $103.41

Q3 2019
Sold the entire position−11.16K shares · No shares reported at quarter-end
Q2 2019
New position+11.16K shares · 11.16K shares reported
Filing context

Quarter-end price $25.72 · Estimated holding basis $25.72

Portfolio importance

How important is Axsome Therapeutics Inc. in Gotham Asset Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#1701of 1791 reported positions
Peak portfolio weight0.0%Q4 2019
Best historical rank#967Q2 2019
At peak importanceQ4 2019
AXSM
0.0%
Largest holding
1.8%
Cross-investor discovery

Who else owns Axsome Therapeutics Inc.?

Also reported by 1 other tracked investor in their latest verified filings.

Ray DalioBridgewater Associates, LP
AXSM0.1% of reported portfolio
Explore Axsome Therapeutics Inc. across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$216.582026-09-14

Market context only; not an investor transaction price.

Latest filing quarter-end price$244.77Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$244.77Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Gotham Asset Management, LLC’s Form 13F disclosures—not Joel Greenblatt’s personal brokerage account. The filing is firm-level rather than a personal stock list. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.